Table 1.
Population | Variant | Clinitest | New-Gene | Boson | Flowflex | Sejoy | Roche |
---|---|---|---|---|---|---|---|
Total cohort | Delta | 72.9% | 75.7% | 77.1% | 70.0% | 74.3% | 92.9% |
(n = 70) | (60.9–82.8) | (64.0–85.2) | (65.6–86.3) | (57.9–80.4) | (62.4–84.0) | (84.1–97.6) | |
Omicron | 69.6% | 73.9% | 78.3% | 67.4% | 73.9% | 78.3% | |
(n = 46) | (54.3–82.3) | (58.9–85.7) | (63.6–89.1) | (52.0–80.5) | (58.9–85.7) | (63.6–89.1) | |
Ct ≤ 25 | Delta | 95.6% | 95.6% | 97.8% | 97.8% | 95.6% | 100% |
(n = 45) | (84.9–99.5) | (84.9–99.5) | (88.2–99.9) | (88.2–99.9) | (84.9–99.5) | (92.1–100) | |
Omicron | 94.1% | 97.1% | 97.1% | 91.2% | 97.1% | 100% | |
(n = 33) | (80.3–99.3) | (84.7–99.9) | (84.7–99.9) | (76.3–98.1) | (84.7–99.9) | (89.4–100) | |
Ct > 25 | Delta | 32.0% | 40.0% | 40.0% | 20.0% | 36.0% | 80.0% |
(n = 25) | (15.0–53.5) | (21.1–61.3) | (21.1–61.3) | (6.8–40.7) | (18.0–57.5) | (59.3–93.2) | |
Omicron | 0.0% | 7.7% | 23.1% | 0.0% | 7.7% | 23.1% | |
(n = 13) | (0.0–24.7) | (0.2–36.0) | (5.0–5.38) | (0.0–24.7) | (0.2–36.0) | (5.0–53.8) | |
Asymptomatic | Delta | 35.3% | 23.5% | 41.2% | 23.5% | 35.3% | 82.4% |
(n = 17) | (14.2–61.7) | (6.8–49.9) | (18.4–67-1) | (6.8–49.9) | (14.2–61.7) | (56.6–96.2) | |
Omicron | 31.3% | 37.5% | 50.0% | 31.3% | 43.8% | 56.3% | |
(n = 16) | (11.0–58.7) | (15.2–64.6) | (24.7–75.4) | (11.0–58.7) | (19.8–70.1) | (29.9–80.3) | |
Symptomatic | Delta | 84.9% | 92.5% | 88.7% | 84.9% | 86.8% | 96.2% |
(n = 53) | (72.4–93.3) | (81.8–97.9) | (77.0–95.7) | (72.4–93.3) | (76.7–94.5) | (87.0–99.5) | |
Omicron | 90.0% | 93.3% | 93.3% | 86.7% | 90.0% | 90.0% | |
(n = 30) | (73.5–97.9) | (77.9–99.2) | (77.9–99.2) | (69.3–96.2) | (73.5–97.9) | (73.5–97.9) |